63140-11-4Relevant academic research and scientific papers
BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF
-
, (2021/12/29)
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS
-
, (2019/05/10)
Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.
HEPATITIS B CORE PROTEIN MODULATORS
-
, (2018/04/13)
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:
Hetero-aromatic compound and its use in medicine (by machine translation)
-
Paragraph 0815; 0816, (2017/08/29)
The invention discloses heteroaromatic compound and its use in medicine, in particular, the invention provides a hetero-aromatic compound or its stereoisomers, geometric isomers, tautomers, racemate, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug, and containing said pharmaceutical composition; the invention also discloses the compound or its pharmaceutical compositions in use for preparing a medicament, and in the treatment of autoimmune diseases or proliferative diseases of application. (by machine translation)
GLYCOSIDASE INHIBITORS
-
, (2014/10/15)
Compounds of formula (I) wherein X1, X2, W, R1 to R5, L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.
QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS
-
Page/Page column 73-74, (2008/06/13)
A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blood
THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER
-
Page 14, (2008/06/13)
The present invention relates to new Macrocycles of formula (I) and their use for the treatment of cancer.
Cyclophanes. 14. Synthesis, Structure Assignment, and Conformational Properties of (2,5)Oxazolo- and Thiazolophanes
Mashraqui, Sabir H.,Keehn, Philip M.
, p. 4461 - 4465 (2007/10/02)
The first synthesis of cyclophanes containing aromatic nuclei with two heteroatoms is described.A Hoffman pyrolytic route was used.Two isomeric (2,5)oxazolophanes (6a and 6b) and two isomeric (2,5)thiazolophanes (13a and 13b) were isolated.In both cases the isomers were found to have the anti-anti and the anti-syn structure.The assignments were made by spectral analysis and variable-temperature nuclear magnetic resonance spectroscopy in the oxazolophane case and on the basis of NMR spectral comparisons between normal (13a and 13b) and deuterated derivatives (14a and 14b) in the thiazolophane case.While the aromatic nuclei in the thiazolophanes were found to be conformationally rigid on the NMR time scale, those in the oxazolophanes were found to be conformationally mobile with a rotational barrier of 17.8 kcal/mol.
